samedan logo
 
 
 
spacer
home > ebr > autumn 2019 > the next-generation purification of monoclonal antibodies
PUBLICATIONS
European Biopharmaceutical Review

The Next-Generation Purification of Monoclonal Antibodies




There is unprecedented pressure on the biopharmaceutical industry to improve the performance of monoclonal antibody (mAb) development and manufacturing processes. There are several factors essential to addressing this challenge, including flexibility (in which product changeover time is reduced), quality (as defined by increased robustness and reliability), speed (in which production and product release are accelerated), and cost reductions in manufacturing and capital expenditure.

Improvements in processes and productivity can enable smaller and simpler facilities and lower costs, leading to several advantages, including the ability to:

• Improve competitiveness and long-term sustainability
• Enable business models for new biologics and novel therapies
• Supply developing countries with affordable biologics
• Reach emerging markets profitably

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gary Skarja is the Head of Membrane Chromatography R&D at Merck. He has 20 years of experience leading dynamic R&D teams in a variety of life sciences sectors, including biopharma, medical device, and cell and gene therapy. Gary holds over 20 patents related to novel polymers, devices, and processes for life sciences applications. He has Bachelor’s and Master’s Degrees in Chemical Engineering from McMaster University, Canada, and a PhD in Chemical Engineering from the University of Toronto, Canada.
spacer
Gary Skarja
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Introduces Parteck® COAT Excipient, a Fast-Dissolving Material for Immediate Release Coating

• Designed to simplify the formulation and coating process for tablets • Optimized particle size leads to fast dissolving and increases coating process efficiency Merck has launched its Parteck® COAT excipient, a new functional material designed for immediate release film coating applications. Parteck® COAT is a particle engineered polyvinyl alcohol (PVA) with a unique particle structure that enables rapid dissolution even at low temperatures leading to an increased process efficiency.
More info >>

White Papers

Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs

World Courier

With a fully integrated GxP-compliant transport, storage and distribution system in place and over 140 wholly owned ISO 9001 - certified offices in more than 50 countries, WORLD COURIER, an AmerisourceBergen® company, is the world’s largest and most experienced provider of specialty courier services. It is uniquely positioned to meet the most demanding industry requirements for managing the global distribution of time - and temperaturesensitive pharmaceutical products and IMPs used commercially or in clinical trials.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement